Related Experiment Video

Updated: Jun 2, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma

S Leclercq1, F Gueugnon, B Boutin

  • 1INSERM, U892, Institut de Recherche Thérapeutique, Université de Nantes, Nantes, France.

The European Respiratory Journal
|May 5, 2011
PubMed

Insights

Epigenetic drugs like 5-azaCdR, VPA, and SAHA show promise against malignant pleural mesothelioma (MPM). Combinations kill cancer cells and enhance immune recognition, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor treatment outcomes.
  • Conventional therapies for MPM have limited efficacy.
  • Epigenetic modifications play a role in MPM development and progression.

Purpose of the Study:

  • To evaluate the anticancer effects of epigenetic drugs (5-aza-2'-deoxycytidine, valproic acid, suberoylanilide hydroxamic acid) on MPM.
  • To assess the impact of these drugs on tumour antigen expression and immune cell recognition.
  • To investigate the efficacy of combined epigenetic drug treatments in a preclinical MPM model.

Main Methods:

  • Human MPM cells were treated with epigenetic drugs alone and in combination.
  • Cytotoxicity, tumour antigen expression, and CD8+ T-cell recognition were measured.
  • Combined treatments were evaluated in a murine model of MPM.

Main Results:

  • Valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) synergized with 5-aza-2'-deoxycytidine (5-azaCdR) to induce MPM cell death.
  • Epigenetic drug combinations increased tumour antigen expression, enhancing recognition by cytotoxic T-cells.
  • In vivo, 5-azaCdR/VPA treatment inhibited tumour growth and promoted an anti-tumour immune response.

Conclusions:

  • Epigenetic drug combinations can effectively kill MPM cells and enhance their immunogenicity.
  • These findings support the development of combined chemotherapeutic and immunotherapeutic strategies for MPM.
  • Targeting epigenetic mechanisms offers a promising avenue for novel MPM treatments.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...